Although further clinical studies of CD109 are required to improve these limitations, CD109 is expected to be a novel prognostic marker or therapeutic target for HNSCC in cases with lymph node metastasis. The gene discussed is CD109; the disease is metastatic malignant neoplasm in the lymph nodes.